WINDTREE THERAPEUTICS INC /DE/ (WINT): Nasdaq/NYSE listing notice — Windtree receives Nasdaq deficiency notice for bid price below $1.00

WINDTREE THERAPEUTICS INC /DE/

Deficiency letter received January 22, 2024; common stock (WINT) remains listed on Nasdaq Capital Market.
Company has until July 22, 2024 to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant by July 22, a second 180-day period may be available if other listing standards are met.
Company intends to monitor bid price and consider all options, including a reverse stock split.
No assurance that compliance will be achieved or that delisting will be avoided.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

WINDTREE THERAPEUTICS INC /DE/ received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 22, 2024, Windtree Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 31 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”) has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Nasdaq deficiency letter has no immediate effect on the lis

View on SEC.gov

Browse all listing & compliance notices →

WINDTREE THERAPEUTICS INC /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-24-001871

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.